// App-Quantinova.ai

: Treatment with Oral Azacitidine in Elderly Patients with Higher Risk Myelodysplastic Syndromes after Response to Subcutaneous Azacitidine

Researchers

Presenter

  • Valeria Santini

Principal Investigators

  • Cristina Amato

  • Barbara Caciagli

  • Angela Consagra

  • Luca Rigodanza

  • Sven de Pourcq

  • Margherita Cassari

  • Elena Tofacchi

  • Giorgio Mattiuz

  • Marco Gabriele Gabriele Raddi

  • Alessandro Sanna

Medical Centers

  • MDS Unit, Hematology, AOU Careggi, University of Florence, Florence, Italy

  • Department of Experimental and Clinical Medicine, MDS Unit, Hematology, AOU Careggi - University of Florence, Firenze, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

  • Chronic myelomonocytic leukemia

Biomarkers

  • Cluster of Differentiation 34

  • DNA methylation

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Azacitidine

  • Vidaza

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Tolerability

  • Feasibility

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved